BackMolecular Pharmacology (USA), Overview
Molecular Pharmacology (USA), Ltd.

Molecular Pharmacology (USA), Return on Equity

Valuation check: MLPH's ROE is 0.32%, below the sector sector average of 11.3%.

Get informed when a big investor buys or sells

+ Follow

ROE

0.32%

Return on Equity

0.32%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Molecular Pharmacology (USA), (MLPH) FAQ

The latest ROE for MLPH is 0.32%. That is below the sector sector average of 11.3%. Investors often review this figure alongside Molecular Pharmacology (USA),'s historical trend and sector peers before judging valuation or financial health.

Against its sector companies, MLPH currently prints 0.32% for ROE, while the sector average sits near 11.3%. That is roughly 97.2% below the sector mean. Large gaps often invite a closer look at Molecular Pharmacology (USA),'s growth, margins, and balance sheet.

Return on Equity shows how effectively Molecular Pharmacology (USA), converts resources into returns. At 0.32%, MLPH may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting MLPH's ROE (0.32%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.